Insulin Glargine U300 vs Insulin Degludec U100 in Impact on the Glycaemic and Cardiovascular Factors

PHASE4CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 15, 2018

Primary Completion Date

June 27, 2019

Study Completion Date

June 27, 2019

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Degludec

treatment of DM and it's affect on Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles

DRUG

Glargine U300

treatment of DM and it's affect on Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles

Trial Locations (1)

21000

Klinički bolnički Centar Split, Split

All Listed Sponsors
collaborator

Pavle Vrebalov Cindro

UNKNOWN

collaborator

Jonatan Vuković

UNKNOWN

collaborator

Darko Modun

UNKNOWN

collaborator

Božo Smajić

UNKNOWN

collaborator

Gordan Kardum

UNKNOWN

collaborator

Tina Tičinović Kurir

UNKNOWN

collaborator

Doris Rušić

UNKNOWN

collaborator

Ana Šešelja Perišin

UNKNOWN

collaborator

Josipa Bukić

UNKNOWN

lead

University of Split, School of Medicine

OTHER

NCT04692415 - Insulin Glargine U300 vs Insulin Degludec U100 in Impact on the Glycaemic and Cardiovascular Factors | Biotech Hunter | Biotech Hunter